Bronchodilators

Published on 07/02/2015 by admin

Filed under Anesthesiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 1 (1 votes)

This article have been viewed 1474 times

Bronchodilators

Suneerat Kongsayreepong, MD

Three major classes of bronchodilators are used to treat bronchoconstriction: β-adrenergic receptor agonists, methylxanthines, and anticholinergic agents. The β-adrenergic receptor agonists are further divided into catecholamines, resorcinols, and saligenins.

β-adrenergic receptor agonists

Selective β2-receptor agonists relax bronchioles and uterine smooth muscle without affecting the heart via β1-receptor stimulation. These drugs activate adenyl cyclase, which converts adenosine triphosphate (ATP) to cyclic adenosine 3´-5´-monophosphate (cAMP), which in turn causes relaxation of smooth muscle, resulting in bronchodilation. Nonselective β-receptor agonists used for bronchodilation include epinephrine, isoproterenol, and isoetharine. Selective β2-receptor agonists include albuterol, terbutaline, metaproterenol, and others (Table 94-1). Side effects associated with the use of nonselective medications include increased heart rate, contractility, and myocardial O2 consumption. Selective β2-receptor agonists may also produce some cardiac effects, especially if administered subcutaneously or intravenously. Hypokalemia and hyperglycemia may also occur. Chronic use can be associated with tachyphylaxis.

Table 94-1

Bronchodilators

Adapted, with permission, from Peruzzi WT, Shapiro BA. Respiratory care. In: Murray MJ, Cousin DB, Pearl RG, Prough DS, eds. Critical Care Medicine: Perioperative Management. 2nd ed. Philadelphia: Lippincott-Raven; 2002:428-446.

Drug Trade Name(s) Delivery Mode/Route Mechanism of Action
β-Adrenergic Receptor Agonists
Isoproterenol 0.05% Isuprel Nebulizer Prototypical β-adrenergic receptor agonists, significant β1 side effects
Albuterol 0.5% Ventolin
Proventil
Oral, DPI MDI/nebulizer β2-Adrenergic receptor agonists, increase in cAMP
Isoetharine hydrochloride, 1% Bronkosol MDI/nebulizer β2-Adrenergic receptor agonists, increase in cAMP
Metaproterenol sulfate 5% Alupent
Metaprel
MDI/nebulizer/oral β2-Adrenergic receptor agonists, increase in cAMP
Terbutaline 0.1%   Oral/SQ/Nebulizer/IV β2-Adrenergic receptor agonists
Methylxanthines
Aminophylline Somophyllin Oral/IV Inhibition of cAMP breakdown by phosphodiesterase
Theophylline Respbid, Slo-Bid, Theo-24Theolair Oral/IV Adenosine antagonism
Anticholinergics
Atropine sulfate 2% or 5% Abboject SQ, IM, IV, Nebulizer Cholinergic blocker, decreased cGMP
Ipratropium bromide 0.02% Atrovent MDI/nebulizer Cholinergic blocker, decreased cGMP

image

cAMP, Cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; IM, intramuscular; IV, intravenous; MDI, metered-dose inhaler; SQ, subcutaneous.

Therapeutic aerosols may be administered, preferably, by a metered-dose inhaler (MDI) or as a wet aerosol from a nebulizer containing the medication. Only particles with a diameter of 1 to 5 μm are efficiently deposited in the lower respiratory tract, which is one of the primary reasons that 13% of the output from MDIs, compared with only 1% to 5% of the output from nebulizers, reaches the lower respiratory tract. Propellants used in MDIs are blends of liquefied gas chlorofluorocarbons (CFCs) that can damage the earth’s ozone layer; in addition, some patients are sensitive to these propellants, resulting in bronchospasm. Because of these concerns, some MDIs use hydrofluoroalkanes (HFAs) as the propellant. The HFA formulations of albuterol and ipratropium bromide have been shown to be equivalent to their respective CFC formulations. However, the delivered dose of HFA-formulated beclomethasone dipropionate is five times greater than the dose delivered with the original CFC formulation.

A breath-activated nebulizer, a new type of jet nebulizer, has a low dead-space volume and nebulizes only on inspiration. With this type of nebulizer, waste during exhalation should be completely eliminated. The delivered dose can be more than three times greater than the dose delivered with continuous nebulization.

The use of continuous bronchodilator therapy is sometimes necessary for the treatment of severe bronchospasm, such as for status asthmaticus. In such situations, a low dose of a bronchodilator (e.g., albuterol, 10-15 mg/h) should be used, and the patient should be continuously monitored for side effects (e.g., tachycardia, arrhythmias, hypokalemia) and worsening of symptoms.

Dry-powder inhalers (DPIs) deliver drugs in powder form to the lung. When using this type of inhaler, patients must generate sufficient inspiratory flow rate (≥50 L/min). Generating this level of inspiratory flow rate may be difficult for patients to achieve if they are in acute respiratory distress, especially during severe asthmatic attack.

Catecholamines

Catecholamines are potent and effective bronchodilators that have a rapid onset of action, reach their peak effect quickly, and have a short duration of action (0.5-3 h). These drugs are useful when rapid onset is needed.

Epinephrine has both α-adrenergic and β-adrenergic properties. A dose of 0.3 to 0.5 mg given subcutaneously is commonly used to treat acute bronchospasm. The effects are rapid, peaking in 5 to 25 min, and improvements in pulmonary function are seen for up to 4 h. Side effects include increased heart rate, cardiac output, and systolic blood pressure and decreased diastolic blood pressure and systemic vascular resistance.

Of the sympathomimetics, isoproterenol is the most potent β-adrenergic receptor agonist. It is effective when administered intravenously or inhaled. However, it has essentially been replaced by selective β2-adrenergic receptor agonists.

Resorcinols

Resorcinols are β-adrenergic receptor agonists with a rapid onset and longer duration of action. These are well absorbed from the gastrointestinal tract and can be given orally.

Metaproterenol, a selective β2-adrenergic resorcinol, is available as a solution for aerosol delivery, as a tablet, as a syrup, and for use in an MDI. Onset is 5 to 15 min, with a peak effect at 30 to 60 min and a duration of 3 to 4 h. As a resorcinol, metaproterenol has hydroxyl groups at the 3 and 5 positions of the phenyl ring (as opposed to catecholamines, which have them at the 3 and 4 positions). It is, therefore, resistant to metabolism by catechol-O-methyltransferase (COMT) and has a longer duration of action than most catecholamines. It has enough structural similarities to isoproterenol that metaproterenol has substantial cardiac side effects.

Terbutaline, a selective β2-adrenergic receptor agonist, has an onset of action in 5 to 15 min, a peak of action over 30 to 60 min, and a duration of action lasting 4 to 6 h. A dose of 0.25 mg administered subcutaneously is an alternative treatment for acute severe bronchospasm when the cardiac effects of epinephrine must be avoided. However, when given subcutaneously, terbutaline will have some β1-adrenergic effects and may cause ventricular arrhythmias in patients who have been anesthetized with halothane.

Saligenins

Saligenins are the most recently developed β-adrenergic receptor agonists and have the most β2-receptor specificity. Drugs in this group have a rapid onset of action and a duration of action of about 4 to 6 h.

Albuterol, a selective β2-adrenergic receptor agonist, has very few side effects; cardiac effects are unlikely when the dose of albuterol is less than 400 μg. Its onset of action is 15 min, with a peak effect in 30 to 60 min and a duration of 4 to 6 h. Albuterol is available as a syrup, oral tablet, extended-release tablet, nebulizer solution, MDI, and DPI.

Salmeterol is a very lipophilic, selective β2-adrenergic receptor agonist that must diffuse through the phospholipid membrane before reaching the receptor site. Its onset of action is very slow; therefore, this drug cannot be used as a rescue medication. Salmeterol has a very long duration of action.

Formoterol is a selective β2-adrenergic receptor agonist with a rapid onset of action (within 2-3 min) and a long duration of action (12 h). However, this medication cannot be used as a rescue drug because of potential toxicity.

Methylxanthines

Theophylline is a poorly soluble methylxanthine found in high concentrations in tea leaves. Methylxanthines inhibit the breakdown of cAMP by phosphodiesterase. Aminophylline is the water-soluble salt of theophylline that can be administered orally (3-6 mg/kg) or intravenously (loading dose of 5 mg/kg, followed by 0.5-1.0 mg·kg−1·h−1). Therapeutic plasma concentrations of theophylline are between 5 and 15 μg/mL, although levels as low as 5 μg/mL have been shown to be clinically effective.

Aminophylline works in vitro by inhibiting phosphodiesterase and, thereby, cAMP breakdown. The in vivo mechanism of aminophylline is less clear. Antiinflammatory actions on neutrophils, sympathetic stimulation, and adenosine antagonism are possible mechanisms. The narrow therapeutic range of aminophylline and the potential for arrhythmias developing in patients with the use of this drug have made its use in the perioperative setting controversial. Theophylline is principally metabolized by the liver, and 10% is excreted unchanged in urine. Smokers metabolize the drug faster than do nonsmokers. Heart failure, liver disease, and severe respiratory obstruction all slow the metabolism of theophylline and increase the likelihood of toxicity. Metabolism is slowed by cimetidine and β-adrenergic receptor antagonists.

Theophylline improves pulmonary function and resolves obstruction, in a dose-dependent manner, in patients with reactive airway disease. The drug decreases pulmonary vascular resistance and increases cardiac output. The cardiac-stimulating effects of theophylline are still seen in the presence of β blockade because xanthines are not receptor dependent. Theophylline and caffeine have been shown to decrease the number and duration of apneic episodes in preterm infants.

Side effects with the use of theophylline are often seen when plasma levels exceed 20 μg/mL. The most frequent side effects are nausea and vomiting. Seizures may result from toxic levels and are likely to occur when plasma concentrations exceed 40 μg/mL. Tachycardia and other arrhythmias may also occur with high plasma levels. Theophylline facilitates neuromuscular transmission; thus, patients receiving theophylline may require higher than normal doses of nondepolarizing neuromuscular blocking agents.

Anticholinergic agents

Cholinergic mechanisms play a major role in mediating reflex bronchoconstriction, and anticholinergic drugs may be used to reduce these responses. These medications have been found to be somewhat more effective than β-adrenergic receptor agonists in some patients with chronic bronchitis and emphysema. In the management of asthma, anticholinergic agents are generally less effective than are β-adrenergic receptor agonists, but in acute asthma, a combination of the two types of agents may produce a greater response. Atropine sulfate, a parasympatholytic that can relax airway smooth muscle, can also be given by nebulizer. Because atropine reduces mucociliary clearance and causes other central nervous system and cardiovascular side effects, even at low doses, this medication is not commonly used as a bronchodilator.

Ipratropium bromide, a quaternary amine delivered by nebulizer or MDI, has little systemic absorption. Its bronchodilator effects begin within minutes, with a peak effect in 1 to 2 h. Ipratropium has little or no effect on mucociliary clearance from the lung and little or no effect on heart rate, blood pressure, and gastrointestinal tract. Ipratropium is also available in combination with albuterol.

Antiinflammatory agents

Antiinflammatory agents, such as cromolyn sodium, which stabilize mast cell membranes and thereby intervene in the inflammatory process, are frequently used to treat bronchospastic diseases. Corticosteroids block both the initial immune response and the subsequent inflammatory process. Corticosteroids do not have direct effects on bronchial smooth muscle relaxation but do facilitate the effects of β2-adrenergic receptor agonists. Even though the cellular and biochemical effects are immediate, the full clinical effects take longer; the increase in β-adrenergic receptor agonist response occurs within 2 h, and β-adrenergic receptor agonist density increases within 4 h. Systemically administered steroids, such as hydrocortisone or methylprednisolone, may be required in patients with poor responses to β2-adrenergic receptor agonists over 1 to 2 h. Inhaled corticosteroids, such as beclomethasone, flunisolide, and triamcinolone, which are available as MDIs, DPIs, and nebulizer solutions, are then used to minimize systemic side effects. Symptoms usually improve in 1 to 2 weeks, with maximal response most often occurring in 4 to 8 weeks.